This company seems to have been delisted
Reason: Merged with Opus Genetics
Last recorded trade on: December 26, 2024
Source: https://finance.yahoo.com/news/ocuphire-pharma-merges-opus-genetics-213102859.html
Reason: Merged with Opus Genetics
Last recorded trade on: December 26, 2024
Source: https://finance.yahoo.com/news/ocuphire-pharma-merges-opus-genetics-213102859.html
Ocuphire Pharma
OCUP
S$1.51
Share price
-12.03%
Change (1 day)
-33.18%
Change (1 year)
Categories
Revenue for Ocuphire Pharma (OCUP)
Revenue in 2024 (TTM): S$11.01 Million
According to Ocuphire Pharma's latest financial reports the company's current revenue (TTM 
) is S$10.79 Million. In 2023 the company made a revenue of S$25.15 Million a decrease over the revenue in the year 2022 that were of S$53.42 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ocuphire Pharma from 2020 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | S$11.01 M | -56.22% |
| 2023 | S$25.15 M | -52.91% |
| 2022 | S$53.42 M | 6609.1% |
| 2021 | S$0.79 M | |
| 2020 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Onconova Therapeutics ONTX | S$0.29 M | -97.30% | 🇺🇸 USA |
 OPKO Health
OPK | S$0.88 B | 8,125.84% | 🇺🇸 USA |